Emerging role of GPRC6A variants in alzheimer's disease and tauopathies - alzheimer's disease (ad), tauopathies, and the broader spectrum of ad-related dementias (ADRDS) represent a growing public…

Active Grant Awarded

Award ID
R01AG100290
Recipient
Awarding agency
Obligated
$646,688

Award facts

Assistance listing
93.866 Aging Research
Completion date 4% complete
Place of performance
Lexington, KY 40506, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded The University of Kentucky Research Foundation $646,688 on September 9, 2026, under Grant R01AG100290, Aging Research (CFDA 93.866). The award funds research on how GPRC6A haplotypes modulate tau pathogenesis in Alzheimer's disease and tauopathies. Aim 1 characterizes the effects of the H0 and H1 GPRC6A haplotypes on tau deposition, cognition, and transcriptomic alterations in early- versus late-stage tauopathy models, using novel GPRC6A variant knock-in mice. Aim 2 defines how cell-type-specific gain-of-function expression of GPRC6A variants in neurons versus microglia modulates tau. The period of performance runs from the award date through August 31, 2031. Place of performance is Lexington, Kentucky 40506. Dollars obligated equal the total funding amount. The source identifies no sub-recipients for this award. The assistance type is grant.

Description

Emerging role of GPRC6A variants in alzheimer's disease and tauopathies - alzheimer's disease (ad), tauopathies, and the broader spectrum of ad-related dementias (ADRDS) represent a growing public health crisis with no effective disease-modifying therapies. A convergent hallmark of aging and neurodegeneration consist of impaired protein homeostasis, potentially driven by disruptions in nutrient-sensing pathways. Normally, nutrient availability and proteostatic mechanisms are tightly coordinated; however, becomes uncoupled with age, chronic stress, and disease. Emerging evidence implicates altered arginine metabolism in cerebrospinal fluid, plasma, and brain tissue of individuals with mild cognitive impairment (MCI) and ad. GPRC6A is a G-protein coupled receptor that binds L-arginine and related amino acids and functions as a positive regulator of mechanistic target of rapamycin complex 1 (MTORC1) signaling. Notably, human- specific GPRC6A single nucleotide polymorphisms (SNPS) modify receptor localization and signaling function. Our preliminary data indicate that genetic repression of GPRC6A in tauopathy models mitigates TAU pathology, improves cognitive function, and reverses transcriptomic signatures linked to autophagy, synaptic transmission, mtor signaling, and proteotoxic stress. Importantly, GPRC6A is upregulated in neurons and microglia of ad brains. Analysis from the national alzheimer's coordinating center (NACC) reveals that the GPRC6A H0 haplotype associates with increased braak stage, whereas the ancestral H1 haplotype appears protective. This proposal will investigate how GPRC6A haplotypes modulate TAU pathogenesis. Aim 1 will characterize the effects of H0 and H1 GPRC6A haplotypes on TAU deposition, cognition, and transcriptomic alterations in early versus late-stage tauopathy models using novel GRPC6A variant knock-in mice. Aim 2 will define how cell-type specific gain-of-function expression of GPRC6A variants (in neurons VS. Microglia) modulates TAU pathology using CRE- loxp systems. Aim 3 will evaluate the efficacy of novel GPRC6A-targeted pharmacological agents in haplotype- specific contexts to determine their impact on TAU clearance and therein phenotypes. Collectively, this work addresses critical knowledge gaps regarding how nutrient-sensing receptor variants influence ad progression and explores their therapeutic potential as modulators of ADRDS.

Transactions

Action Obligated Date
Amendment $296,688
Original award $350,000

Quick answers

Who received award R01AG100290?

R01AG100290 was awarded to The University Of Kentucky Research Foundation by National Institute on Aging (National Institutes of Health) on September 9, 2026.

How much is award R01AG100290 worth?

$646,688 has been obligated on R01AG100290.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award